NeoNeuro recently received a new grant from BPI France to advance research on developing aptamers as diagnostic and therapeutic tools for Alzheimer’s disease. This funding enables our team to accelerate the discovery and optimization of aptamers that can precisely detect disease-associated biomarkers in blood. Additionally, the grant supports our efforts to explore aptamers’ potential as targeted therapeutic agents, offering new approaches to treat or slow the progression of Alzheimer’s. By leveraging this support, NeoNeuro aims to move closer to creating innovative, minimally invasive solutions for earlier diagnosis and more effective intervention in Alzheimer’s disease.